Taken together, these findings suggest that Polθ inhibitors have the potential to improve patient response to therapy in combination with various targeted approaches in specific genetic backgrounds, including PARPi treatment in HRD cancers and NHEJ inhibition in TP53-mutant cancers. Here, TP53 is linked to cancer.